Steven R Steinhubl

Summary

Publications

  1. ncbi request reprint Aspirin to prevent cardiovascular disease: the association of aspirin dose and clopidogrel with thrombosis and bleeding
    Steven R Steinhubl
    The Medicines Company, Balsberg, 8058 Zurich Flughafen, Switzerland
    Ann Intern Med 150:379-86. 2009
  2. ncbi request reprint Historical observations on the discovery of platelets, platelet function testing and the first antiplatelet agent
    Steven R Steinhubl
    The Geisinger Health System, Danville, PA 17822, USA
    Curr Drug Targets 12:1792-804. 2011
  3. doi request reprint Why have antioxidants failed in clinical trials?
    Steven R Steinhubl
    Geisinger Clinic, Geisinger Center for Health Research, 100 North Academy Avenue, Danville, PA 17822, USA
    Am J Cardiol 101:14D-19D. 2008
  4. doi request reprint Bleeding complications with dual antiplatelet therapy among patients with stable vascular disease or risk factors for vascular disease: results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHAR
    Peter B Berger
    Director, Center for Clinical Studies, 100 N Academy Ave, MC 44 00, Danville, PA 17822, USA
    Circulation 121:2575-83. 2010
  5. doi request reprint Is there a clinically significant interaction between calcium channel antagonists and clopidogrel?: results from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial
    Christopher W Good
    Geisinger Clinic, Danville, PA, USA
    Circ Cardiovasc Interv 5:77-81. 2012
  6. doi request reprint Ticagrelor: the first novel reversible P2Y(12) inhibitor
    Wah Wah Htun
    Geisinger Medical Center, Department of Cardiology, Danville Pennsylvania, 100N Academy Ave, MC 27 70, Danville, PA 17822, USA
    Expert Opin Pharmacother 14:237-45. 2013
  7. doi request reprint A brief review of the past and future of platelet P2Y12 antagonist
    Kulpreet Barn
    Geisinger Medical Center, Danville, Pennsylvania 17822, USA
    Coron Artery Dis 23:368-74. 2012
  8. ncbi request reprint Relation of platelet inactivation with intravenous glycoprotein IIb/IIIa antagonists to major bleeding (from the GOLD study)
    Michael R Tamberella
    Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA, USA
    Am J Cardiol 89:1429-31. 2002
  9. doi request reprint Frequency of major noncardiac surgery and subsequent adverse events in the year after drug-eluting stent placement results from the EVENT (Evaluation of Drug-Eluting Stents and Ischemic Events) Registry
    Peter B Berger
    Geisinger Clinic, Danville, Pennsylvania 17822 4400, USA
    JACC Cardiovasc Interv 3:920-7. 2010
  10. ncbi request reprint Variable response to antiplatelet therapy: what does it mean to clinicians?
    Nezar Falluji
    Linda and Jack Gill Heart Institute, University of Kentucky, Lexington, USA
    Cleve Clin J Med 74:49-55. 2007

Collaborators

Detail Information

Publications10

  1. ncbi request reprint Aspirin to prevent cardiovascular disease: the association of aspirin dose and clopidogrel with thrombosis and bleeding
    Steven R Steinhubl
    The Medicines Company, Balsberg, 8058 Zurich Flughafen, Switzerland
    Ann Intern Med 150:379-86. 2009
    ..The optimal aspirin dose for the prevention of cardiovascular events remains controversial...
  2. ncbi request reprint Historical observations on the discovery of platelets, platelet function testing and the first antiplatelet agent
    Steven R Steinhubl
    The Geisinger Health System, Danville, PA 17822, USA
    Curr Drug Targets 12:1792-804. 2011
    ..For the current and future pioneers of platelet research an understanding of how we got to where we are today will hopefully allow for a clearer and inspired vision of where we will go next...
  3. doi request reprint Why have antioxidants failed in clinical trials?
    Steven R Steinhubl
    Geisinger Clinic, Geisinger Center for Health Research, 100 North Academy Avenue, Danville, PA 17822, USA
    Am J Cardiol 101:14D-19D. 2008
    ..Rather, these results challenge us to evaluate optimal antioxidant therapies, the ideal study patients to study, and the appropriate trial duration...
  4. doi request reprint Bleeding complications with dual antiplatelet therapy among patients with stable vascular disease or risk factors for vascular disease: results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHAR
    Peter B Berger
    Director, Center for Clinical Studies, 100 N Academy Ave, MC 44 00, Danville, PA 17822, USA
    Circulation 121:2575-83. 2010
    ..We sought to determine the frequency and time course of bleeding with DAPT in patients with established vascular disease or risk factors only; identify correlates of bleeding; and determine whether bleeding is associated with mortality...
  5. doi request reprint Is there a clinically significant interaction between calcium channel antagonists and clopidogrel?: results from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial
    Christopher W Good
    Geisinger Clinic, Danville, PA, USA
    Circ Cardiovasc Interv 5:77-81. 2012
    ..Several studies have reported that CCBs reduce the ability of clopidogrel to inhibit platelet aggregability; one suggested that CCBs reduce the efficacy of clopidogrel...
  6. doi request reprint Ticagrelor: the first novel reversible P2Y(12) inhibitor
    Wah Wah Htun
    Geisinger Medical Center, Department of Cardiology, Danville Pennsylvania, 100N Academy Ave, MC 27 70, Danville, PA 17822, USA
    Expert Opin Pharmacother 14:237-45. 2013
    ..Combination therapy with aspirin and one of the P2Y(12) inhibitors (clopidogrel, prasugrel, or most recently, ticagrelor ) has been recommended by both ACC/AHA and ESC guidelines for ACS patients...
  7. doi request reprint A brief review of the past and future of platelet P2Y12 antagonist
    Kulpreet Barn
    Geisinger Medical Center, Danville, Pennsylvania 17822, USA
    Coron Artery Dis 23:368-74. 2012
    ..Recently, new thienopyridine plus nonthienopyridine P2Y12 antagonists have become available or are being studied that will further improve our treatment of patients with coronary disease...
  8. ncbi request reprint Relation of platelet inactivation with intravenous glycoprotein IIb/IIIa antagonists to major bleeding (from the GOLD study)
    Michael R Tamberella
    Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA, USA
    Am J Cardiol 89:1429-31. 2002
  9. doi request reprint Frequency of major noncardiac surgery and subsequent adverse events in the year after drug-eluting stent placement results from the EVENT (Evaluation of Drug-Eluting Stents and Ischemic Events) Registry
    Peter B Berger
    Geisinger Clinic, Danville, Pennsylvania 17822 4400, USA
    JACC Cardiovasc Interv 3:920-7. 2010
    ..This study sought to determine the frequency of noncardiac surgery and adverse post-operative events among patients who recently received a drug-eluting stent (DES) following noncardiac surgery...
  10. ncbi request reprint Variable response to antiplatelet therapy: what does it mean to clinicians?
    Nezar Falluji
    Linda and Jack Gill Heart Institute, University of Kentucky, Lexington, USA
    Cleve Clin J Med 74:49-55. 2007
    ....